Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Revenue Compound Annual Growth Rate in the last 5 years.
Operating Income Compound Annual Growth Rate in the last 5 years.
Net Income Compound Annual Growth Rate in the last 5 years.
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
...and much more!